Stocktoria

Pyxis Oncology, Inc. PYXS

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2021-10-08

Pyxis Oncology, Inc. statistics & valuation

Market cap$175.5M
P / S12.7×
P / B3.3×
Net margin-574.5%
Return on equity-149.1%
FCF margin-458.3%
Return on capital-119.9%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Net margin (%)
-478.90% -574.50% 202020212022202320242025
Gross margin (%)
202020212022202320242025
Operating margin (%)
-554.10% -609.20% 202020212022202320242025
Return on equity (%)
-29.10% -75.10% -58.70% -64.00% -149.10% 202020212022202320242025
Shares outstanding
1.3M 32.2M 35.0M 44.8M 60.0M 62.7M 202020212022202320242025
Net debt ($)
202020212022202320242025
Share buybacks ($)
202020212022202320242025
Return on assets (%)
-126.40% -27.10% -57.10% -42.50% -49.20% -87.00% 202020212022202320242025
Free cash flow margin (%)
-358.70% -458.30% 202020212022202320242025
Debt / equity (×)
202020212022202320242025
EPS ($)
-$8.95 -$3.65 -$1.85 -$1.32 -$1.28 202020212022202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2022FY2021FY2020
Operating margin-609.2%-554.1%————
Net margin-574.5%-478.9%————
FCF margin-458.3%-358.7%————
Return on assets-87.0%-49.2%-42.5%-57.1%-27.1%-126.4%
Return on equity-149.1%-64.0%-58.7%-75.1%-29.1%82.0%
Current ratio3.417.494.845.9014.902.20

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.